Aleksandr I. Kirienko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Aleksandr I. Kirienko has a total of 147 co-authors. Here are the top co-authors by number of shared publications:
- Igor Anatolievich Zolotukhin
Pirogov Russian National Research Medical University
10 shared publications - Mariya Aleksandrovna Smetanina
Laboratory of Pharmacogenomics, Institute of Chemical Biology and Fundamental Medicine (ICBFM) SB RAS, Novosibirsk 630090, Russia
5 shared publications - Alexander Vyacheslavovich Sazhin
Pirogov Russian National Research Medical University
4 shared publications - Alexandra Sergeevna Shadrina
Laboratory of Theoretical and Applied Functional Genomics, Novosibirsk State University, Novosibirsk, Russia
4 shared publications - Evgenii Arkadievich Ilyukhin
Medalp Surgical Clinic
4 shared publications Andrey I Shevela
Institute of Chemical Biology and Fundamental Medicine, Russia
2 shared publications
Latest Publications
- 25 November 2024
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 11,p. 5-23
Acute appendicitis in adults
Acute appendicitis in adults. Clinical guidelines.
- 25 November 2024
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 11,p. 5-23
Acute appendicitis in adults
Acute appendicitis in adults. Clinical guidelines.
- Open Access
- 23 October 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (11) , 6157
Non-immunogenic staphylokinase — a thrombolytic agent in the treatment of massive pulmonary embolism: results of the FORPE clinical trial
Aim. To assess the safety and efficacy of a single intravenous bolus of non-immunogenic staphylokinase compared with alteplase in patients with massive pulmonary embolism and hemodynamic instability. Non-immunogenic staphylokinase is a modified recombinant staphylokinase with low immunogenicity, high thrombolytic activity and fibrin selectivity.Material and methods. This multicenter, open-label, randomized, comparative clinical trial FORPE in two parallel groups was conducted in 23 clinical centers in Russia. A total of 310 patients aged 18 years and older with hemodynamic instability and computed tomography pulmonary angiography verified massive pulmonary embolism and right ventricular dysfunction were included. The patients were randomly assigned in either non-immunogenic staphylokinase (15 mg) or alteplase (100 mg) group. Both medicines were administered intravenously. An independent biostatistician created a randomization sequence using computer-generated random numbers. Randomization was performed using the envelopes. The study was open-label, and emergency unit staff, investigators, and patients were informed about the assigned drug. The primary efficacy endpoint was 7-day all-cause death after randomization. The non-inferiority margin was set at 10% for the difference in 7-day all-cause mortality after randomization between the compared groups. Non-inferiority was tested using the Welch t-test for the primary efficacy endpoint. Secondary efficacy endpoints were analyzed in both the intention-to-treat and per-protocol populations.Results. Of 348 patients screened between December 25, 2020, and July 31, 2023, 310 (89%) were included in the study. Of the total number, 155 (50%) patients were randomized to the non-immunogenic staphylokinase group and 155 (50%) to the alteplase group. In the non-immunogenic staphylokinase group, the primary efficacy endpoint, 7-day all-cause death, was 2% in the intent-to-treat population and 2% in the per-protocol population, whereas in the alteplase group it was 3% (odds ratio (OR) 0,75, 95% confidence interval (CI) 0,11-4,49; p=1,00) and 3% (OR 0,75, 95% CI 0,11-4,52; p=1,00), respectively. The difference in the primary efficacy endpoint was 0,6% (95% CI -2,8 to -4,0) in the intent-to-treat population and 0,6% (95% CI -2,9 to -4,2) in the per-protocol population. Thus, the lower limit of the 95% CI did not cross the non-inferiority margin (pConclusion. Non-immunogenic staphylokinase is at least as effective as alteplase in the treatment of patients with massive pulmonary embolism with hemodynamic instability and has a higher safety profile. Future observational studies of non-immunogenic staphylokinase are needed to continue assessing its safety and efficacy. Given the high safety and efficacy of non-immunogenic staphylokinase, its use should be studied in patients with moderate-to-high risk pulmonary embolism.
- 23 October 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (11) , 6157
Open AccessNon-immunogenic staphylokinase — a thrombolytic agent in the treatment of massive pulmonary embolism: results of the FORPE clinical trial
Aim. To assess the safety and efficacy of a single intravenous bolus of non-immunogenic staphylokinase compared with alteplase in patients with massive pulmonary embolism and hemodynamic instability. Non-immunogenic staphylokinase is a modified recombinant staphylokinase with low immunogenicity, high thrombolytic activity and fibrin selectivity.Material and methods. This multicenter, open-label, randomized, comparative clinical trial FORPE in two parallel groups was conducted in 23 clinical centers in Russia. A total of 310 patients aged 18 years and older with hemodynamic instability and computed tomography pulmonary angiography verified massive pulmonary embolism and right ventricular dysfunction were included. The patients were randomly assigned in either non-immunogenic staphylokinase (15 mg) or alteplase (100 mg) group. Both medicines were administered intravenously. An independent biostatistician created a randomization sequence using computer-generated random numbers. Randomization was performed using the envelopes. The study was open-label, and emergency unit staff, investigators, and patients were informed about the assigned drug. The primary efficacy endpoint was 7-day all-cause death after randomization. The non-inferiority margin was set at 10% for the difference in 7-day all-cause mortality after randomization between the compared groups. Non-inferiority was tested using the Welch t-test for the primary efficacy endpoint. Secondary efficacy endpoints were analyzed in both the intention-to-treat and per-protocol populations.Results. Of 348 patients screened between December 25, 2020, and July 31, 2023, 310 (89%) were included in the study. Of the total number, 155 (50%) patients were randomized to the non-immunogenic staphylokinase group and 155 (50%) to the alteplase group. In the non-immunogenic staphylokinase group, the primary efficacy endpoint, 7-day all-cause death, was 2% in the intent-to-treat population and 2% in the per-protocol population, whereas in the alteplase group it was 3% (odds ratio (OR) 0,75, 95% confidence interval (CI) 0,11-4,49; p=1,00) and 3% (OR 0,75, 95% CI 0,11-4,52; p=1,00), respectively. The difference in the primary efficacy endpoint was 0,6% (95% CI -2,8 to -4,0) in the intent-to-treat population and 0,6% (95% CI -2,9 to -4,2) in the per-protocol population. Thus, the lower limit of the 95% CI did not cross the non-inferiority margin (pConclusion. Non-immunogenic staphylokinase is at least as effective as alteplase in the treatment of patients with massive pulmonary embolism with hemodynamic instability and has a higher safety profile. Future observational studies of non-immunogenic staphylokinase are needed to continue assessing its safety and efficacy. Given the high safety and efficacy of non-immunogenic staphylokinase, its use should be studied in patients with moderate-to-high risk pulmonary embolism.
- 24 March 2023
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 17 (1)
Response to Comment to the Article “Does the Use of Prognostic Scales and Clinical Guidelines Always Guarantee the Survival of Patients with Massive Pulmonary Embolism”
Response to Comment to the Article “Does the Use of Prognostic Scales and Clinical Guidelines Always Guarantee the Survival of Patients with Massive Pulmonary Embolism”.
- 24 March 2023
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 17 (1)
Response to Comment to the Article “Does the Use of Prognostic Scales and Clinical Guidelines Always Guarantee the Survival of Patients with Massive Pulmonary Embolism”
Response to Comment to the Article “Does the Use of Prognostic Scales and Clinical Guidelines Always Guarantee the Survival of Patients with Massive Pulmonary Embolism”.
- 1 January 2022
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 9,p. 92-95
Laparoscopic transchiatal access in Boerhaave syndrome
Диагностика спонтанного разрыва пищевода (синдром Бурхаве), который приводит к развитию гнойного медиастинита и эмпиемы плевры, в настоящее время значительно упростилась в связи с возможностью использования КТ. Главное — своевременно заподозрить этот синдром. Способы оперативного лечения этого заболевания до сих пор обсуждаются. Представляем случай успешного хирургического лечения спонтанного разрыва пищевода с использованием видеолапароскопии.
- 1 January 2022
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 9,p. 92-95
Laparoscopic transchiatal access in Boerhaave syndrome
Диагностика спонтанного разрыва пищевода (синдром Бурхаве), который приводит к развитию гнойного медиастинита и эмпиемы плевры, в настоящее время значительно упростилась в связи с возможностью использования КТ. Главное — своевременно заподозрить этот синдром. Способы оперативного лечения этого заболевания до сих пор обсуждаются. Представляем случай успешного хирургического лечения спонтанного разрыва пищевода с использованием видеолапароскопии.
- 1 January 2022
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 16 (2)
Non-Immunogenic Staphylokinase vs Alteplase in Patients with Massive Pulmonary Embolism: the Protocol of a Multiple-Center Open-Label Randomized Trial FORPE
ЦЕЛЬ Клинического исследования ФОРПЕ — оценка эффективности и безопасности неиммуногенной стафилокиназы при ее однократном болюсном введении в сравнении с болюсно-инфузионным введением алтеплазы у пациентов с массивной тромбоэмболией легочных артерий. МАТЕРИАЛ И МЕТОДЫ Неиммуногенная стафилокиназа обладает высокой тромболитической активностью и фибринселективностью. Клиническое исследование ФОРПЕ — многоцентровое открытое рандомизированное сравнительное исследование «не меньшей эффективности» (non-inferiority) в двух параллельных группах. На клинических базах пациенты (общее число 310 человек с учетом возможного 10% выбывания) с подтвержденным по данным мультиспиральной компьютерной томография с контрастированием легочных артерий диагнозом «массивная тромбоэмболия легочных артерий» будут поровну рандомизированы методом конвертов на две группы для назначения неиммуногенной стафилокиназы или алтеплазы. В протоколе исследования представлены критерии включения и невключения, расчет объема необходимой выборки пациентов и план проведения исследования. Основной критерий оценки эффективности тромболитической терапии с применением неиммуногенной стафилокиназы или алтеплазы — смерть от всех причин в течение 7 сут. Критерии безопасности — ишемический и геморрагический инсульт в течение 7 сут после тромболизиса и кровотечения по критериям BARC (3-го и 5-го типов). РЕЗУЛЬТАТЫ По итогам исследования будут получены данные об эффективности и безопасности неиммуногенной стафилокиназы у пациентов с массивной тромбоэмболией легочных артерий; составлен отчет с приложениями индивидуальных данных и статистического анализа результатов. Результаты исследования будут опубликованы и представлены на конференциях. РЕГИСТРАЦИЯ Протокол исследования ФОРПЕ утвержден Минздравом России (№16 от 15.01.19 с дополнениями от 05.07.21), Советом по этике Минздрава России (№182 от 04.12.18) и зарегистрирован на clinicaltrials.gov (№NCT04688320, FORPE).
- 1 January 2022
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 16 (2)
Non-Immunogenic Staphylokinase vs Alteplase in Patients with Massive Pulmonary Embolism: the Protocol of a Multiple-Center Open-Label Randomized Trial FORPE
ЦЕЛЬ Клинического исследования ФОРПЕ — оценка эффективности и безопасности неиммуногенной стафилокиназы при ее однократном болюсном введении в сравнении с болюсно-инфузионным введением алтеплазы у пациентов с массивной тромбоэмболией легочных артерий. МАТЕРИАЛ И МЕТОДЫ Неиммуногенная стафилокиназа обладает высокой тромболитической активностью и фибринселективностью. Клиническое исследование ФОРПЕ — многоцентровое открытое рандомизированное сравнительное исследование «не меньшей эффективности» (non-inferiority) в двух параллельных группах. На клинических базах пациенты (общее число 310 человек с учетом возможного 10% выбывания) с подтвержденным по данным мультиспиральной компьютерной томография с контрастированием легочных артерий диагнозом «массивная тромбоэмболия легочных артерий» будут поровну рандомизированы методом конвертов на две группы для назначения неиммуногенной стафилокиназы или алтеплазы. В протоколе исследования представлены критерии включения и невключения, расчет объема необходимой выборки пациентов и план проведения исследования. Основной критерий оценки эффективности тромболитической терапии с применением неиммуногенной стафилокиназы или алтеплазы — смерть от всех причин в течение 7 сут. Критерии безопасности — ишемический и геморрагический инсульт в течение 7 сут после тромболизиса и кровотечения по критериям BARC (3-го и 5-го типов). РЕЗУЛЬТАТЫ По итогам исследования будут получены данные об эффективности и безопасности неиммуногенной стафилокиназы у пациентов с массивной тромбоэмболией легочных артерий; составлен отчет с приложениями индивидуальных данных и статистического анализа результатов. Результаты исследования будут опубликованы и представлены на конференциях. РЕГИСТРАЦИЯ Протокол исследования ФОРПЕ утвержден Минздравом России (№16 от 15.01.19 с дополнениями от 05.07.21), Советом по этике Минздрава России (№182 от 04.12.18) и зарегистрирован на clinicaltrials.gov (№NCT04688320, FORPE).
- 1 January 2022
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 16 (1)
Does the Use of Prognostic Scales and Clinical Guidelines Always Guarantee the Survival of Patients with Massive Pulmonary Embolism
Массивная тромбоэмболия легочных артерий (ТЭЛА) при несвоевременной диагностике и лечении может привести к смерти пациента в острой стадии заболевания или развитию тяжелой постэмболической легочной гипертензии в отдаленном периоде. Современные клинические рекомендации, составленные разными врачебными сообществами, помогают выбрать надлежащую лечебную тактику. Тем не менее шаблонное выполнение рекомендаций может приводить к негативным результатам. ЦЕЛЬ РАБОТЫ На клиническом примере показать необходимость многостороннего похода к решению тактических вопросов, основанного на сочетании прогностических шкал, клинических рекомендаций и врачебной интуиции, к ведению пациентов с острым венозным тромбозом, осложненным массивной ТЭЛА. МАТЕРИАЛ И МЕТОДЫ Представлено наблюдение пациента с переломом костей голени, осложнившимся развитием тромбоза глубоких вен и массивной ТЭЛА. Несмотря на соблюдение современных клинических рекомендаций, наступил летальный исход в результате рецидива ТЭЛА. Проведен анализ клинической ситуации, сделаны предположения о причинах такого исхода и нереализованных альтернативных вариантах врачебных действий. ЗАКЛЮЧЕНИЕ Клинические рекомендации не являются универсальным механизмом выбора лечебной тактики. Необходимо дополнять предлагаемые ими алгоритмы индивидуальной оценкой ситуации и принимать решение, основываясь на комплексном клиническом подходе.
- 1 January 2022
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 16 (1)
Does the Use of Prognostic Scales and Clinical Guidelines Always Guarantee the Survival of Patients with Massive Pulmonary Embolism
Массивная тромбоэмболия легочных артерий (ТЭЛА) при несвоевременной диагностике и лечении может привести к смерти пациента в острой стадии заболевания или развитию тяжелой постэмболической легочной гипертензии в отдаленном периоде. Современные клинические рекомендации, составленные разными врачебными сообществами, помогают выбрать надлежащую лечебную тактику. Тем не менее шаблонное выполнение рекомендаций может приводить к негативным результатам. ЦЕЛЬ РАБОТЫ На клиническом примере показать необходимость многостороннего похода к решению тактических вопросов, основанного на сочетании прогностических шкал, клинических рекомендаций и врачебной интуиции, к ведению пациентов с острым венозным тромбозом, осложненным массивной ТЭЛА. МАТЕРИАЛ И МЕТОДЫ Представлено наблюдение пациента с переломом костей голени, осложнившимся развитием тромбоза глубоких вен и массивной ТЭЛА. Несмотря на соблюдение современных клинических рекомендаций, наступил летальный исход в результате рецидива ТЭЛА. Проведен анализ клинической ситуации, сделаны предположения о причинах такого исхода и нереализованных альтернативных вариантах врачебных действий. ЗАКЛЮЧЕНИЕ Клинические рекомендации не являются универсальным механизмом выбора лечебной тактики. Необходимо дополнять предлагаемые ими алгоритмы индивидуальной оценкой ситуации и принимать решение, основываясь на комплексном клиническом подходе.
- Open Access
- 30 March 2020
- Published by Paediatrician Publishers LLC in Annals of the Russian academy of medical sciences
- Vol. 75 (1) , 36-45
Varicose veins: on the verge of discovering the cause?
Varicose veins of the lower limbs are one of the most common and wide-spread pathology all around the world. What triggers the specific changes in a vein wall still remains unclear as well as what happens in the layers of the vein wall after the disease starts. The aim of the article is to analyze published data and results of researches on epidemiology, genetics, cellular and molecular mechanisms underlying varicose veins pathogenesis. It is now commonly accepted that vein wall changes in patients with varicose veins result from vein-specific inflammation. This process includes leukocytes adhesion to venous endothelium with their subsequent migration into the vein wall and surrounding tissues. Activated leukocytes express a number of molecules that lead to vein wall remodeling and dilation. Comprehensive assessment of the epidemiological data on the prevalence of varicose veins and risk factors, of the findings from genetic studies, of data on molecular-cell interactions as well as results of various surgical interventions in patients with varicose veins, shows that remodeling is a reversible process that can be stopped and reversed by different stimuli including some chemical substances. For the first time in the literature, the authors assume that varicose veins can be successfully cured pharmacologically with no surgical interventions needed.
- 30 March 2020
- Published by Paediatrician Publishers LLC in Annals of the Russian academy of medical sciences
- Vol. 75 (1) , 36-45
Open AccessVaricose veins: on the verge of discovering the cause?
Varicose veins of the lower limbs are one of the most common and wide-spread pathology all around the world. What triggers the specific changes in a vein wall still remains unclear as well as what happens in the layers of the vein wall after the disease starts. The aim of the article is to analyze published data and results of researches on epidemiology, genetics, cellular and molecular mechanisms underlying varicose veins pathogenesis. It is now commonly accepted that vein wall changes in patients with varicose veins result from vein-specific inflammation. This process includes leukocytes adhesion to venous endothelium with their subsequent migration into the vein wall and surrounding tissues. Activated leukocytes express a number of molecules that lead to vein wall remodeling and dilation. Comprehensive assessment of the epidemiological data on the prevalence of varicose veins and risk factors, of the findings from genetic studies, of data on molecular-cell interactions as well as results of various surgical interventions in patients with varicose veins, shows that remodeling is a reversible process that can be stopped and reversed by different stimuli including some chemical substances. For the first time in the literature, the authors assume that varicose veins can be successfully cured pharmacologically with no surgical interventions needed.
- 14 May 2019
- Published by Springer Nature in Hernia
- Vol. 23 (6) , 1237-1242
Prevalence and risk factors for abdominal wall hernia in the general Russian population
To find out the prevalence and risk factors for abdominal wall hernias in the general Russian population.
- 14 May 2019
- Published by Springer Nature in Hernia
- Vol. 23 (6) , 1237-1242
Prevalence and risk factors for abdominal wall hernia in the general Russian population
To find out the prevalence and risk factors for abdominal wall hernias in the general Russian population.
- Open Access
- 30 March 2018
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 14 (1) , 57-67-67
Intraoperative and oncological results of treating patients with renal cell carcinoma and venous tumor thrombus
Background. The general characteristic of renal cell cancer is metastatic invasion of tumor thrombus in the inferior vena cava (IVC). Objective is the evaluation of the results of surgical treatment of patients with renal cell carcinoma and venous tumor thrombus.Materials and methods. During the period from 2011 to April 2017 in the Clinic of Urology at the N.I. Pirogov City Clinical Hospital No. 1 26 radical/cytoreductive nephrectomies with thrombectomy were conducted. Men predominated (n = 20 (76.9 %)) over women (n = 6 (23.1 %)) among the patients. Median age – 64 years (47–82 years). 14 (53.8 %) patients were diagnosed with disease of the right kidney and 12 (46.2 %) of the left kidney. Level I (n = 12 (46.2 %)) – renal vein, perirenal part of the IVC. Level II (n = 8 (30.8 %)) – infrahepatic part of the IVC. Level III (n = 5 (19.2 %)) – retrohepatic part of the IVC. Level IV (n = 1 (3.8 %)) – supradiaphragmatic (intrapericardial, intra-atrial) part of the IVC. Enlarged retroperitoneal lymph nodes were detected in 11 (42.3 %) cases based on the data received from computed tomography scan. 6 (23.1 %) patients were diagnosed with distant metastases at the time of operation: solitary in 4 (15.4 %) cases, multiple in 2 (7.7 %) cases.Results. All interventions ocurred without intraoperative lethality. Median operative time – 212 minutes (140–335 minutes). Blood loss median 300 ml (50–5000 ml). Blood salvage (Cell-Saver) was used on 4 (15.4 %) patients due to major blood loss. In 4 (15.4 %) cases one of single-plane operations was performed (cholecystectomy, atypical hepatic resection, prosthetic repair of abdominal region of aorta, resection of the IV liver segment, left hemicolectomy (T4, malignant invasion in descending colon)). Postoperative complications were registered in 8 (30.8 %) cases. Lethality in the early (30 days) postoperative period equaled 7.7 % (n = 2).Conclusion. Radical/cytoreductive nephrectomies with thrombectomy from the IVC is a technically complex surgery. It should be performed in expert centers with material and technical resources for such operations.
- 30 March 2018
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 14 (1) , 57-67-67
Open AccessIntraoperative and oncological results of treating patients with renal cell carcinoma and venous tumor thrombus
Background. The general characteristic of renal cell cancer is metastatic invasion of tumor thrombus in the inferior vena cava (IVC). Objective is the evaluation of the results of surgical treatment of patients with renal cell carcinoma and venous tumor thrombus.Materials and methods. During the period from 2011 to April 2017 in the Clinic of Urology at the N.I. Pirogov City Clinical Hospital No. 1 26 radical/cytoreductive nephrectomies with thrombectomy were conducted. Men predominated (n = 20 (76.9 %)) over women (n = 6 (23.1 %)) among the patients. Median age – 64 years (47–82 years). 14 (53.8 %) patients were diagnosed with disease of the right kidney and 12 (46.2 %) of the left kidney. Level I (n = 12 (46.2 %)) – renal vein, perirenal part of the IVC. Level II (n = 8 (30.8 %)) – infrahepatic part of the IVC. Level III (n = 5 (19.2 %)) – retrohepatic part of the IVC. Level IV (n = 1 (3.8 %)) – supradiaphragmatic (intrapericardial, intra-atrial) part of the IVC. Enlarged retroperitoneal lymph nodes were detected in 11 (42.3 %) cases based on the data received from computed tomography scan. 6 (23.1 %) patients were diagnosed with distant metastases at the time of operation: solitary in 4 (15.4 %) cases, multiple in 2 (7.7 %) cases.Results. All interventions ocurred without intraoperative lethality. Median operative time – 212 minutes (140–335 minutes). Blood loss median 300 ml (50–5000 ml). Blood salvage (Cell-Saver) was used on 4 (15.4 %) patients due to major blood loss. In 4 (15.4 %) cases one of single-plane operations was performed (cholecystectomy, atypical hepatic resection, prosthetic repair of abdominal region of aorta, resection of the IV liver segment, left hemicolectomy (T4, malignant invasion in descending colon)). Postoperative complications were registered in 8 (30.8 %) cases. Lethality in the early (30 days) postoperative period equaled 7.7 % (n = 2).Conclusion. Radical/cytoreductive nephrectomies with thrombectomy from the IVC is a technically complex surgery. It should be performed in expert centers with material and technical resources for such operations.
- 15 December 2017
- Published by Springer Nature in Immunologic Research
- Vol. 66 (1) , 141-150
Polymorphisms in inflammation-related genes and the risk of primary varicose veins in ethnic Russians
Inflammation was shown to be activated in varicose veins, although its role in the development of vein wall transformation remains inconclusive. We aimed to investigate the influence of 13 inflammation-related single nucleotide polymorphisms (SNPs) TNF rs1800629 and rs3093661, IL1A rs1800587, IL1RN rs4251961, IL6 rs1800795 and rs1800796, IFNG rs2430561, IL10 rs1800896, TGFB1 rs1800469, HIF1A rs11549465, NFKB1 rs28362491, and rs4648068 on the risk of primary varicose veins (PVVs) in ethnic Russians. We genotyped 709 patients with PVVs and 278 individuals without a history of chronic venous disease and performed a single SNP and a haplotype analysis. Several associations with P < 0.05 were revealed in our study. Variant allele HIF1A rs11549465 T, TNF rs3093661 A, and NFKB1 rs28362491 ATTG deletion showed the reverse association with PVV risk, and allele IL6 rs1800795 C was associated with the increased risk of the studied pathology. Haplotype analysis revealed associations of TNF haplotypes rs3093661 A-rs1800629 G and IL6 rs1800795 C-rs1800796 G with the decreased and the increased risk of PVVs, correspondingly. However, all the observed associations failed to reach statistical significance after the correction for multiple testing, which was set at a level of 10−3 due to many tests performed. Our study therefore provides evidence that investigated polymorphisms do not play a major role in susceptibility to PVVs.
- 15 December 2017
- Published by Springer Nature in Immunologic Research
- Vol. 66 (1) , 141-150
Polymorphisms in inflammation-related genes and the risk of primary varicose veins in ethnic Russians
Inflammation was shown to be activated in varicose veins, although its role in the development of vein wall transformation remains inconclusive. We aimed to investigate the influence of 13 inflammation-related single nucleotide polymorphisms (SNPs) TNF rs1800629 and rs3093661, IL1A rs1800587, IL1RN rs4251961, IL6 rs1800795 and rs1800796, IFNG rs2430561, IL10 rs1800896, TGFB1 rs1800469, HIF1A rs11549465, NFKB1 rs28362491, and rs4648068 on the risk of primary varicose veins (PVVs) in ethnic Russians. We genotyped 709 patients with PVVs and 278 individuals without a history of chronic venous disease and performed a single SNP and a haplotype analysis. Several associations with P < 0.05 were revealed in our study. Variant allele HIF1A rs11549465 T, TNF rs3093661 A, and NFKB1 rs28362491 ATTG deletion showed the reverse association with PVV risk, and allele IL6 rs1800795 C was associated with the increased risk of the studied pathology. Haplotype analysis revealed associations of TNF haplotypes rs3093661 A-rs1800629 G and IL6 rs1800795 C-rs1800796 G with the decreased and the increased risk of PVVs, correspondingly. However, all the observed associations failed to reach statistical significance after the correction for multiple testing, which was set at a level of 10−3 due to many tests performed. Our study therefore provides evidence that investigated polymorphisms do not play a major role in susceptibility to PVVs.